期刊文献+

广东人群CYP3A4*1G等位基因分布频率调查

Investigation of CYP3A4*1G allele frequency in Guangdong population
下载PDF
导出
摘要 目的探讨CYP3A4*1G等位基因在广东人群中的分布特征,为广东患者使用CYP3A4底物药提供参考依据。方法提取192例广东人外周血DNA,分别用PCR扩增其CYP3A4基因跨越第10内含子20230G>A位点的DNA片段,PCR产物用AfaⅠ酶切,通过酶切产物的电泳图谱判断基因型。结果 GG、GA、AA 3种基因型的频率分别为63.5%、30.7%、5.7%。等位基因20230A即CYP3A4*1G的频率为21.1%。结论广东人群存在较高频率的CYP3A4*1G等位基因,在使用CYP3A4底物药时应密切关注患者是否存在该突变位点。 Objective To investigate the distribution characteristics of CYP3A4 * 1G polymorphisms in Guangdong population. Methods Total 192 subjects were collected in Guangdong population and blood genomie DNA was used as template. DNA fragment spanning the tenth intron of CYP3A4 (20230G 〉 A) was amplified by polymerase chain reaction (PCR), followed by digestion with restriction enzyme Afa I. Subsequently, the gene type was defined by restriction fragment length polymorphism (RFLP). Results The frequencies of wild- type homozygous (GG), heterozygous (GA) and mutation bomozygous (AA) genotypes were 63.5% ,30.7%, 5.7% ,respectively. The frequency of allele 20230A ( CYP3A4 * 1G) in Guangdong population was 21.1%. Conclusion There is an allele high frequency of CYfr3A4 * 1G in Guangdong population, which suggests that detection of CYP3A4 * 1G genotype may be helpful :for individual clinical therapy, especially when CYP3A4 substrate drugs are used.
出处 《广东药学院学报》 CAS 2013年第6期665-667,共3页 Academic Journal of Guangdong College of Pharmacy
基金 2012年广东省大学生创新实验项目(1057312040)
关键词 广东人群 CYP3A4*1G 基因多态性 Guangdong population CYP3A4 * 1 G polymorphism
  • 相关文献

参考文献16

  • 1RENDIC S,di CARLO F J.Human cytochrome P450 enzymes:a status report summarizing their reactions,substrates,inducers,and inhibitors[J].Drug Metab Rev,1997,29 (1/2):413-580.
  • 2FUJITA K.Food-drug interactions via human cytochrome P450 3A (CYP3A)[J].Drug Metabol Drug Interact,2004,20(4):195-217.
  • 3FISHELOVITCH D,SHAIK S,WOLFSON H J,et al.Theoretical characterization of substrate access/exit channels in the human cytochrome P450 3A4 enzyme:involvement of phenylalanine residues in the gating mechanism[J].J Phys Chem B,2009,113 (39):13018-13025.
  • 4FISHELOVITCH D,SHAIK S,WOLFSON H J,et al.How does the reductase help to regulate the catalytic cycle of cytochrome P450 3A4 using the conserved water channel[J].J Phys Chem B,2010,114(17):5964-5970.
  • 5DAI D,TANG J,ROSE R,et al.Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos[J].Pharmacol Exp Ther,2001,299 (3):825-831.
  • 6ZHANG Wei,CHANG Yanzi,KAN Quancheng,et al.CYP3A4 * 1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients[J].Eur J Clin Pharmacol,2010,66(1):61-66.
  • 7GAO Yuan,ZHANG Lirong,FU Qiang.CYP3A4 * 1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin[J].Eur J Clin Pharmacol,2008,64(9):877-882.
  • 8BURTON M E,SHAW L M,SCHENTAG J J,et al.Applied pharmacokinetics & pharmacodynamics:principles of therapeutic drug monitoring[M].4th ed.Baltimore,MD:Lippincott Williams & Wilkins,2006:121-127.
  • 9ZHOU Shufeng,CHAN Eli,LI Xiaotian,et al.Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4[J].Ther Clin Risk Manag,2005,1 (1):3-13.
  • 10EISELT R,DOMANSKI T L,ZIBAT A,et al.Identification and functional characterization of eight CYP3A4 protein variants[J].Pharmacogenetics,2001,11(5):447-458.

二级参考文献32

  • 1吴家骅.难治性癫癎的诊断与治疗[J].中华儿科杂志,2005,43(5):386-389. 被引量:25
  • 2RENDIC S, di CARLO FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitor[J]. Drug Metab Rev, 1997, 29(1-2): 413-580.
  • 3ZHANG W, CHANG YZ, KAN QC, et al. CYP3A4*IG genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients[J]. Eur J Clin Pharmaeol, 2010,66(1): 61-66.
  • 4ZHU B, CHEN GL, CHEN XP, et al. Genotype of CYP3AP1 associated with CYP3A activity in Chinese Han population [J]. Acta Pharmacol Sin, 2002, 23(6): 567-572.
  • 5GAO Y, ZHANG LR, FU Q. CYP3A4*IG polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin[J]. Eur J Clin Pharmacol, 2008, 64(9): 877-882.
  • 6KUEHL P, ZHANG J, LIN Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001, 27 (4): 383-391.
  • 7DU J, YU L, WANG L, et al. Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations[J]. Clin Chim Acta, 2007, 383(1-2) : 172-174.
  • 8FUKUSHIMA-UESAKA H, SAITO Y, WATANABE H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population[J]. Hum Mutat, 2004, 23 (1): 100.
  • 9MACPHEE IA, FREDERICKS S, TAI T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of eytochrome p4503A5 and P-glycoprotein correlate with dose requirement[J]. Transplantation, 2002, 74 ( 11 ) : 1496-1499.
  • 10COOPER TA, MATTOX W. The regulation of splice-site selection, and its role in human disease[J]. Am J Hum Genet, 1997, 61 (2) : 259-266.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部